3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Skin Neoplasms in 1 studies
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.
Skin Neoplasms: Tumors or cancer of the SKIN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wen, Y | 1 |
| Li, J | 1 |
| Koo, J | 1 |
| Shin, SS | 1 |
| Lin, Y | 1 |
| Jeong, BS | 1 |
| Mehnert, JM | 1 |
| Chen, S | 1 |
| Cohen-Sola, KA | 1 |
| Goydos, JS | 1 |
1 other study available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Skin Neoplasms
| Article | Year |
|---|---|
Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression.
Topics: Angiogenesis Inhibitors; Animals; Cell Movement; Heterocyclic Compounds, 3-Ring; Humans; Hypoxia-Ind | 2014 |